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Structural studies of human G protein-coupled
receptors (GPCRs) have recently been accelerated
through the use of a fusion partner that was inserted
into the third intracellular loop. Using chimeras of the
human b2-adrenergic and human A2A adenosine
receptors, we present the methodology and data
for the initial selection of an expanded set of fusion
partners for crystallizing GPCRs. In particular, use
of the thermostabilized apocytochrome b562RIL as
a fusion partner displays certain advantages over
previously utilized fusion proteins, resulting in a
significant improvement in stability and structure of
GPCR-fusion constructs.
INTRODUCTION
G protein-coupled receptors (GPCRs) encompass the largest
family of cell surface receptors, and are responsible for the cell’s
ability to recognize a variety of external stimuli, including
hormones, neurotransmitters, lipids, peptides, and light (Bjarna-
do´ttir et al., 2006). As a result of the enormous efforts devoted to
studying the structural characteristics of these receptors, prog-
ress is accelerating but remains comparatively slow. Major
hurdles associated with crystallizing GPCRs manifest at all
stages in the process, including protein expression, purification,
and crystallization. Receptors of immediate interest may not
always be easily expressed to sufficient quantities required for
crystallization studies, and even if that hurdle is overcome, the
stability ofGPCRsmaybecompromised at thepurification stage,
during which the protein must be removed from its native bilayer
environment (Chae et al., 2010; Serrano-Vega et al., 2008). Addi-
tionally, GPCRs are inherently dynamic proteins, sampling
a range of conformations between active and inactive signaling
states. This flexibility, along with the scarcity of hydrophilic
regions available to form potential crystal contacts, are major
impediments to obtaining diffraction quality GPCR crystals.
The level of difficulty associated with GPCR crystallization is
evidenced by the fact that despite significant effort, rhodopsin
is the only wild-type (WT) receptor to have been successfully
crystallized (Palczewski et al., 2000). For all other GPCRs, crys-Structure 20tallization has required protein engineering using a combination
of the following approaches: (1) truncation of flexible N- and/or
C-terminal domains, (2) implementation of point mutations in
order to stabilize the receptor in a specific conformation (Lebon
et al., 2011; Miller and Tate, 2011; Serrano-Vega et al., 2008),
and (3) insertion of a fusion partner into the third intracellular
loop (ICL3) (Cherezov et al., 2007; Rosenbaum et al., 2007), or
more recently at the receptor N terminus (Rasmussen et al.,
2011b; Thompson et al., 2012). Although the truncation of termini
has been employed for most GPCR constructs, successful crys-
tallization has also required further protein engineering or the
addition of stabilizing antibodies as in case of the b2-adrenergic
receptor (b2AR) (Rasmussen et al., 2007; Day et al., 2007). More
recently, the antibody method has also successfully enabled
crystallization of the A2A adenosine receptor (A2AAR) (Hino
et al., 2012). Point mutations found via exhaustive alanine-scan-
ning helped to stabilize and crystallize the b1-adrenergic receptor
(b1AR) (Warne et al., 2008), as well as A2AAR (Dore´ et al., 2011;
Lebon et al., 2011). To date, the most successful methodology
has been the T4 lysozyme (T4L) engineering method, which
enabled the crystallization of the b2AR (Hanson et al., 2008; Cher-
ezov et al., 2007; Rasmussen et al., 2011a; Wacker et al., 2010),
A2AAR (Jaakola et al., 2008; Xu et al., 2011b), chemokine CXCR4
receptor (Wu et al., 2010), dopamine D3 receptor (Chien et al.,
2010), histamine H1 receptor (Shimamura et al., 2011), sphingo-
sine phosphate S1P1 receptor (Hanson et al., 2012), muscarinic
acetylcholine M2 (Haga et al., 2012), and M3 (Kruse et al., 2012)
receptors, m-opioid receptor (Manglik et al., 2012), d-opioid
receptor (Granier et al., 2012), and k-opioid receptor (Wu et al.,
2012).
Although the replacement of ICL3 with T4L has already proven
its utility in GPCR crystallization, we found that a number of
GPCRs were not amenable to this approach due to deleterious
effects on the expression or stability of the chimeric protein.
With approximately 800 GPCRs in humans (Bjarnado´ttir et al.,
2006) and a growing demand for higher resolution structures,
the determination of GPCR crystal structures remains in its
infancy. The continuous development of new approaches in
order to expand the repertoire of GPCR crystallization tools will
be paramount in moving the field forward. Here, we report the
identification and development of GPCR fusion proteins to facil-
itate GPCR crystallization efforts. Starting with the initial
proposal to insert soluble fusion proteins into membrane protein, 967–976, June 6, 2012 ª2012 Elsevier Ltd All rights reserved 967
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Prive´ et al., 1994) and a review of the Protein Data Bank (PDB),
a number of fusion candidates were evaluated that possessed
characteristics deemed suitable for enhancing crystallizability
of membrane proteins. From this effort five fusion proteins
were selected and examined. Of the five considered in this study,
thermostabilized apocytochrome b562RIL showed great utility in
the crystallization of multiple GPCRs with superior characteris-
tics relative to T4L that has been used previously.
RESULTS
Selection of Chimeric Partners and Design
of Constructs
ICL3 has highly variable length and pronounced structural
flexibility inmanyGPCRsas shownby its highproteolytic suscep-
tibility and high hydrogen-deuterium exchange rate (West et al.,
2011). When present in a construct sequence, it is often found
disordered in crystallized GPCRs (Palczewski et al., 2000; Warne
et al., 2008). Based on past successes, and for the reasons
mentioned above, this receptor region was therefore chosen as
the site for fusion partner insertion. Optimal insertion into ICL3
requires the N and C termini of a fusion partner to be separated
by a distance similar to the distance between the intracellular
ends of helices V and VI (6–14 A˚) as found in existingGPCR struc-
tures. This allows the fusion domain to be inserted without signif-
icantly disrupting the fold of the fusion domain or the core struc-
ture of the membrane spanning helices in the GPCR of interest.
We used the following search criteria to define fusion partners
from suitable single domain proteins in the PDB: (1) crystal struc-
ture at higher than 2.0 A˚ resolution andmean B-factor lower than
40, factors that usually correlate with an acceptable stability of
the domain and its propensity to form crystal contacts, (2)
a molecular weight between 5–20 kDa, to exclude both small
unstable peptides and large/multidomain proteins with complex
folding kinetics, (3) a difference between the number of basic and
acidic residues N(Arg,Lys)  N(Asp,Glu) in the range of 20 to
10, to exclude highly charged protein domains; and (4) a distance
between the N- and C-terminal Ca atoms of <15 A˚ for optimal
insertion. The search was also limited to bacterial proteins to
avoid issues with posttranslational modification, and to entries
with a single protein chain to eliminate oligomerization inter-
faces. A search of the PDB with the above criteria yielded 193
nonredundant protein domains (Table S1 available online).
Further selection of the domains was performedmanually by first
excluding domain fragments (except for the C-terminal fragment
of T4 lysozyme) and uncharacterized protein hits to narrow the
list to proteins that have been previously characterized bio-
chemically and validated to be members of their predicted
family. Greater weight was placed on hits that had high represen-
tation within the PDB and the availability of apo X-ray or NMR
structural data. Structures were manually reviewed to ensure
that the N and C termini were not buried or part of a highly
structured region of the fold. Additionally, disulfide containing
proteins were eliminated due to the cytoplasmic location of the
ICL3 fusions. From that reduced set, emphasis was placed on
maximizing diversity of both fold and molecular weight.
To test the selection criteria, five initial fusion partners were
considered: a C-terminal fragment of T4 lysozyme (with mutation968 Structure 20, 967–976, June 6, 2012 ª2012 Elsevier Ltd All rightsC39A, PDB ID 2O7A, henceforth referred to as CtermT4L), flavo-
doxin (PDB ID 1I1O), xylanase (PDB ID 2B45), rubredoxin
(PDB ID 1FHM), and thermostabilized apocytochrome b562
(with mutations M7W, H102I, R106L, PDB ID 1M6T, henceforth
referred to as BRIL), (Figure 1). This set of fusion protein candi-
dates exhibits a variety of secondary structure elements ranging
from being almost completely composed of loops (rubredoxin),
b sheets (xylanase), a helices (BRIL andCtermT4L), and a combi-
nation of all these elements (flavodoxin). The ICL3 of A2AAR and
b2AR were replaced with each of these domains to assess their
utility in expression, purification, stability, and crystallization. For
a complete list of constructs and details regarding insertion sites
into the respective receptors, please refer to Figure 2. Construct
numbers from Figure 2 will also be referenced in the remainder of
the text to preclude ambiguity.
Assessment of A2A Adenosine Receptor Chimeras
Expression and Purification
Spodoptera frugiperda (Sf9) cells expressing the A2AAR
chimeras were disrupted by repeated dounce homogenization,
followed by solubilization with 0.5% (w/v) n-dodecyl-b-D-malto-
side (DDM, Affymetrix) and 0.1% (w/v) cholesteryl hemisuccinate
(CHS, Sigma). Solubilized chimeras were purified by immobilized
metal affinity column (IMAC) purification against a C-terminal
103 His tag. Among the five A2AAR chimeric constructs,
A2AAR-rubredoxin, A2AAR-BRIL, and A2AAR-flavodoxin had
greater recovery of purified protein compared to that of A2AAR-
CtermT4L and A2AAR-xylanase as evidenced by immunoblotting
(Figure 3). Analytical size exclusion chromatography (aSEC) of
the five A2AAR chimeras showed that each eluted mainly as
a single peak, preceded by a minor component, which we attrib-
uted to protein aggregation (Figure 4). Although the elution
profiles of each construct were very similar in terms of shape,
the relative peak sizes corroborated the better purification yield
of A2AAR-flavodoxin, A2AAR-rubredoxin, and A2AAR-BRIL. Due
to the inferior purification recovery of A2AAR-CtermT4L and
A2AAR-xylanase, these two constructs were removed from
consideration in subsequent assays where purified protein was
required.
Thermostability
Due to their inherent flexibility, thermostability is an important
metric in the crystallization of GPCRs. To test the effect of
the fusion domains on the protein, a fluorescence based thermo-
stability assay (Alexandrov et al., 2008) was carried out. A2AAR
constructs were incubated with either an antagonist,
ZM241385, or an agonist, UK432,097, to stabilize the receptor
prior to heating. We found that when bound with ZM241385,
A2AAR-flavodoxin, A2AAR-rubredoxin (construct 7), and A2AAR-
BRIL (construct 12) all had almost identical thermal transition
temperatures, 6C higher than that of the previously studied
A2AAR-T4L (Jaakola et al., 2008) (Figure 5A). When bound with
UK432,097, A2AAR-BRIL and A2AAR-rubredoxin showed similar
thermal transition temperatures, whereas the transition temper-
ature of A2AAR-flavodoxin was reduced by over 10
C when
compared with A2AAR-T4L (Figure 5B). The improved thermo-
stability of A2AAR-BRIL (construct 12) and A2AAR-rubredoxin
(construct 7) in either antagonist or agonist bound conformations
makes them attractive candidates for crystallization trials, as the
availability of multiple highly stabilizing ligands increases thereserved
Figure 1. Five Fusion Domains Selected for Fusion into the Third Intracellular Loop of A2AAR and b2AR
Figure illustrating the insertion of five fusion domains into the ICL3 of a typical GPCR, represented as a transmembrane snake plot. The five domains are
a C-terminal fragment of T4L (PDB ID 2O7A, MW 15.9 kDa), flavodoxin (PDB ID 1I1O, MW 14.9 kDa), xylanase (PDB ID 2B45, MW 19.1 kDa), rubredoxin (PDB ID
1FHM, MW 5.5 kDa), and cytochrome b562RIL (PDB ID 1M6T, MW 10.9 kDa). These domains exhibit a variety of secondary structures consisting of either
a helices, b sheets, or a combination of both. Numbers indicate distance (A˚) between the N and C termini of each domain. T4 Lysozyme (PDB ID 2LZM, MW
18.6 kDa) is shown for reference.
See also Table S1.
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BRIL and A2AAR-rubredoxin were thus selected for further crys-
tallization studies.
Junction Optimization
Initial crystallization trials with either A2AAR-rubredoxin
(construct 7) or A2AAR-BRIL (construct 12) in lipidic cubic phase
(LCP) did not produce any crystals using crystallization screens
described previously (Xu et al., 2011a). Although the reason
for the absence of crystal growth cannot be known for certain,
we further optimized these two A2AAR chimeras by modifying
the junction between the receptor and the insertion domain.
The interface on the A2AAR side of the junction was originally
optimized for the insertion of T4L, which presents a different
secondary structure interface from either BRIL or rubredoxin.
The T4L interface consists of two a helices perpendicular to
each other, BRIL consists of two adjacent a helices anti-parallel
to each other, and rubredoxin is composed of loops. These
considerations led us to test if adding or removing native
residues on the A2AAR side of the junction could improve the
thermostability of the protein. Multiple alternative junction sites
that improved the stability of both A2AAR-rubredoxin and
A2AAR-BRIL (Figures 5C and 5D) were identified. Of these, the
most stabilizing junctions for A2AAR-rubredoxin had the addition
of two residues on helix V (construct 9) or the removal of three
residues on helix VI (construct 10), both of which raised the
stability of the protein by 4C. For A2AAR-BRIL, the
most stabilizing junctions had either the removal (construct 15)
or addition (construct 16) of three residues on the helix VIStructure 20side of the junction, which increased the stability of the protein by
4C.
Protein Diffusion and Crystallization in LCP
The thermostabilized A2AAR-BRIL (construct 16) and A2AAR-
rubredoxin (construct 7) constructs in complex with ZM241385
were further assessed by the high-throughput LCP-FRAP assay
(Xu et al., 2011a). Proteins were preferentially labeled at the
N terminus with Cy3-mono NHS ester at pH 7.5 tominimize inter-
ferences with the protein core. All protein samples were evalu-
ated for purity, monodispersity, and labeling efficiency by
aSEC prior to LCP-FRAP sample preparation. Labeled protein
was reconstituted in LCP by mixing protein solution with molten
lipid in a final ratio of 40% (w/w) protein solution, 54% (w/w)
monoolein, 6% (w/w) cholesterol, and incubated with home-
made screens as introduced previously (Xu et al., 2011a). The
pH for the screens were adjusted to 4.0, 5.0, and 6.0 based on
previous A2AAR crystallization conditions (Jaakola et al., 2008;
Xu et al., 2011b).
A2AAR-BRIL showed optimal mobile fractions at pH 5.0,
which reached 70% diffusion recovery with certain precipitants
(Figure S2). We found that the average mobile fraction of A2AAR-
BRIL throughout the 96-well plate was consistently higher than
that of A2AAR-rubredoxin (Figure S2C), and proceeded with
A2AAR-BRIL for further crystallization trials with a focus on
conditions that produced a mobile fraction recovery higher
than 70%, including citrate, tartrate, nitrate, and thiocyanate.
Crystallization trials were performed in 96-well glass sandwich
plates (Marienfeld) by an NT8-LCP crystallization robot, 967–976, June 6, 2012 ª2012 Elsevier Ltd All rights reserved 969
Figure 2. Diagram of Fusion Partner Insertion Sites for Both A2AAR and b2AR Constructs
The construct number in the first column as well as the alphanumeric insertion site are used as a reference for all the constructs referred to in the main text. For
example, insertion site B2 refers to the initial insertion site of T4L into A2AAR-T4L, between residues L208 and R222.
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Fusion Partners for GPCR Stabilization(Formulatrix) using 40–50 nl protein-laden LCP overlaid with
0.8 ml precipitant solution in each well, and sealed with a glass
coverslip (Caffrey and Cherezov, 2009; Cherezov et al., 2004).
The best diffraction quality crystals were obtained within
7 days in 25%–28% (v/v) PEG 400, 0.04–0.06 M sodium thiocy-
anate, 2% (v/v) 2,5-hexanediol, 100 mM sodium citrate pH 5.0.970 Structure 20, 967–976, June 6, 2012 ª2012 Elsevier Ltd All rightsCrystals grew to an average size of 60 3 10 3 3 mm (Figure 6)
and diffracted to 1.7 A˚ resolution. The crystal structure of
A2AAR-BRIL was solved at 1.8 A˚ resolution, the best resolution
of all GPCRs to date, allowing us to appreciate additional details
that were previously unobservable at lower resolution (Liu et al.,
2012).Figure 3. Purified Chimeras Analyzed by
SDS-PAGE and Visualized by Coomassie
Staining and a-Flag Western Immunoblots
Coomassie stained gels are on the left, and the
equivalent western immunoblots on the right.
Multiple receptor bands are due, in part, to
differential glycosylation states of the receptor,
and can be collapsed after deglycosylation with
PNGaseF and reduction by a reducing agent.
See also Figure S1.
reserved
Figure 4. Analytical Size Exclusion Chromatography Analysis of Each Chimera
Signals represent fluorescence emission at 350 nm (excitation at 280 nm). The rightmost box of each row shows the normalized and overlaid profiles for
comparative purposes. Construct numbers are in parenthesis after construct name.
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Expression and Purification
Each of the five potential fusion partners was cloned into the T4L
insertion site of b2AR and expressed in Sf9 cells. The integrity of
the fusion protein was assessed in a similar manner as with the
A2AAR constructs after purification. b2AR constructs were incu-
bated with 1 mM timolol prior to solubilization with 0.5% (w/v)
DDM and 0.1% (w/v) CHS, followed by IMAC purification against
a C-terminal 103 His tag. b2AR-rubredoxin, b2AR-BRIL, and
b2AR-flavodoxin showed purification recovery levels similar to
that of b2AR-T4L, whereas the b2AR-CtermT4L signal was
weak, and b2AR-xylanase was almost undetectable (Figure 3).
aSEC analysis showed that the elution profiles of most of
the chimeras were very similar to b2AR-T4L in terms of peak
shape, with the exception of b2AR-CtermT4L, which had a
more prominent aggregate component relative to the primary
peak (Figure 4).
Thermostability
The thermostability of the different b2AR constructs was then
evaluated. Assays were carried out in the presence of 1 mM
timolol to maintain receptor stability during heating (Figure 5E).
Relative to b2AR-T4L, b2AR-flavodoxin and b2AR-CtermT4L
were both less stable by 10C, whereas b2AR-xylanase and
b2AR-rubredoxin had similar stability compared to b2AR-T4L.
b2AR-BRIL was more stable than b2AR-T4L by 13C. Thus,
b2AR-BRIL was selected for further crystallization studies.
Protein Diffusion and Crystallization in LCP
We were able to grow crystals of b2AR-BRIL (construct 24) in
LCP without the need for junction site optimization, as wasStructure 20necessary with A2AAR-BRIL. The LCP-FRAP assay was carried
out in similar fashion to A2AAR-BRIL in order to guide crystalliza-
tion trials. Proteins were labeledwith Cy3-monoNHS ester, in pH
7.5 buffer, and likewise evaluated for purity, monodispersity, and
labeling efficiency by aSEC prior to LCP-FRAP sample prepara-
tion. Labeled protein was reconstituted into LCP by mixing
protein solution with molten lipid in a final ratio of 40% (w/w)
protein solution, 54% (w/w) monoolein, 6% (w/w) cholesterol,
and incubated with homemade screens as introduced previ-
ously. The pH for the screens were adjusted to 6.0, 7.0, and
8.0 based on previous b2AR crystallization conditions (Hanson
et al., 2008; Cherezov et al., 2007; Wacker et al., 2010). Among
all three pHs, b2AR-BRIL displayed optimal mobile fractions at
pH 7.0, which reached up to 50% diffusion recovery with certain
precipitants (Figure S2). Crystals were grown in 0.1 M Bis-Tris
propane pH 7.5, 25%–30% (v/v) PEG 400, 0.1–0.3 M ammonium
formate, and 25%–30% (w/v) trimethylamine N-oxide. Opti-
mized crystals grew to803 153 5 mm (Figure 6) and diffracted
anisotropically to a maximum resolution of 2.8 A˚ along the best
axis and 3.7 A˚ along the worst axis.
DISCUSSION
The methodology for identification of fusion partners was vali-
dated by the successful crystallization and X-ray diffraction of
A2AAR-BRIL and b2AR-BRIL fusions in the ICL3 to 1.8 and
3.0 A˚ resolution, respectively. More recently, we have success-
fully determined the structure of the opioid nociceptin/orphanin
FQ peptide receptor at 3.0 A˚ resolution by placing BRIL on the, 967–976, June 6, 2012 ª2012 Elsevier Ltd All rights reserved 971
Figure 5. Normalized Fluorescence-Based Thermostability Profiles
of Receptor-Fusion Chimeras
Thermostability profiles for initial A2AAR chimera screen (constructs 3, 5, 7, 12)
with ZM241385 (A), initial A2AAR chimera screen (constructs 3, 5, 7, 12) with
UK432,097 (B), junction optimization for A2AAR-Rubredoxin with ZM241385
(constructs 7–11) (C), junction optimization for A2AAR-BRIL with ZM241385
(constructs 12–16) (D), and initial b2AR chimera screen (constructs 19–24) with
timolol (E). Construct numbers in parenthesis after name.
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972 Structure 20, 967–976, June 6, 2012 ª2012 Elsevier Ltd All rightsN terminus of the receptor (Thompson et al., 2012). This receptor
did not crystallize with T4L inserted into ICL3 or fused to the N
terminus, further demonstrating the utility of BRIL as a fusion
partner.
Although the biological impact of these structures are beyond
the scope of this methods study, and are reported elsewhere
(Thompson et al., 2012; Liu et al., 2012), a number of structural
details regarding the fusion regions are important for under-
standing how the fusion proteins are engineered into the
receptor. For example, in the 1.8 A˚ A2AAR-BRIL structure (PDB
ID 4EIY), the interface between BRIL and A2AAR consists of
receptor helices V and VI that extend seamlessly into the
a helices of BRIL (Figures 7A and 7B). This is in contrast to the
variable loop interfaces connecting the receptor with the T4L
domain observed in previous GPCR-T4L structures. From
a structural perspective, this has the advantage that the residues
on the receptor side are able to maintain their helical secondary
structure, as opposed to being artificially forced into a different
conformation by the fusion domain. The availability of inactive
A2AAR structures solved by different methods (T4L fusion: PDB
ID 3EML; thermostabilized, with intact ICL3: PDB ID 3PWH)
provides a unique opportunity to examine this. Compared to
the structure of A2AAR with an intact ICL3, the cytoplasmic end
of helix V on A2AAR-T4L breaks into a loop, whereas the end of
helix VI becomes shifted toward helix V. These distortions are
presumably necessary to accommodate the transition from the
receptor to T4L. Conversely, in the A2AAR-BRIL structure, the
protein backbone conformation at the cytoplasmic ends of
helices V and VI closely follows the unmodified ICL3 structure
(PDB ID 3PWH), with the helices continuing into BRIL. The
BRIL chimera thus exhibits minimal distortion of the intracellular
portions of helices V and VI, matching more closely what is seen
in the nonchimeric receptor structure than in the T4L chimera.
From a crystallographic perspective, the junction flexibility in
previous GPCR-T4L chimeras has allowed a wide range of T4L
domain orientations, permitting their crystallization with different
crystal packing contacts. Although this could be beneficial from
the perspective of maximizing crystal contacts, the structure in
the immediate vicinity of the junction between the receptor and
T4L is affected unpredictably by the crystal packing lattice. A
well-defined a-helical junction on the other hand is expected to
be more resistant to such crystallographic disturbances,
providing a more rigid protein overall, but potentially at the
expense of being able to readily crystallize in different forms. It
will be instructive to see how the a-helical junction impacts
the stability and final resolution of other GPCR-BRIL crystal
structures. Insights from such structures and comparisons with
GPCR-T4L structures may allow us to rationally design
improved GPCR-fusion domain junctions for stabilization and
crystallization.
Despite the well-defined helical structure and stability of the
BRIL hydrophobic core, the GPCR-BRIL junction site also
affords some level of plasticity due to inherent flexibility of the
heme-binding region in apo-BRIL that may be beneficial in terms
of accommodating its insertion into adjacent GPCR a helices.
Thus, though the connection between receptor helix V and
BRIL helix I are almost perfectly aligned, receptor helix VI
connects with BRIL helix IV at an angle of 40. This bending
distortion is accommodated by the last two turns of helix IV inreserved
Figure 6. Representative Crystals and Diffraction
of A2AAR-BRIL and b2AR-BRIL in LCP
A2AAR-BRIL/ZM241385 (construct 16) (A) and b2AR-BRIL/
timolol (construct 24) (B). Crystals grew to 60 3 10 3
3 mm for A2AAR-BRIL and 80 3 153 5 mm for b2AR-BRIL.
Inset shows the same image under cross polarized light.
Diffraction patterns for A2AAR-BRIL (C) and b2AR-BRIL
(D). Inset shows magnified view around diffraction spot
enclosed by the red box.
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Fusion Partners for GPCR StabilizationBRIL and is highly flexible in apocytochrome b562, as it exhibits
large conformational variations between NMR models (Feng
et al., 2004) as well as between crystal structures of the
apo- and heme-bound cytochrome b562 (Lederer et al., 1981)
(Figure 7C). Additionally, the long loop connecting helices II
and III in the heme-binding region of BRIL has 16 disordered
residues, which also reflects its highly flexible behavior
described previously in apo-BRIL NMR studies. These observa-
tions reflect a dual nature of BRIL, which is highly flexible in
the heme-binding region, but has a very stable and rigid core
in the distal part that ensures fast folding kinetics and fold
stability (Kimura et al., 2009). This duality makes BRIL an
attractive partner for fusions in the loop regions between
a helices of membrane proteins, as it can easily accommodate
minor lateral misalignments between the a helices of the two
proteins, and at the same time help with folding kinetics and
stability.
With this new toolchest of fusion partners for membrane
protein structural biology and the knowledge gained, it is of
interest to see if the initial PDB search criteria could be refined
to incorporate what we have learned thus far to enable the
rational selection of improved fusion domains. Such improve-
ments could include fluorescent or colored proteins, or ones
with other advantageous signaling capabilities for biophysical
investigations. Furthermore, we have evaluated the use of fusion
partners in the termini of GPCRs to aid in the expression, stabi-
lization, and crystal packing, including the successful structure
determination of the nociceptin/orphanin FQ peptide receptor
(Thompson et al., 2012). Notwithstanding the different consider-
ations involved in selecting termini fusion domains, the scope ofStructure 20, 967–976, June 6crystallizable membrane proteins could be
vastly expanded by examining fusions in all
extracellular and intracellular loops and termini.
The successful matching of fusion partners with
membrane proteins will not only improve forth-
coming GPCR crystal structure determination
efforts, but also serve as a platform to accelerate
progress in the crystallization of other mem-
brane proteins and even larger protein assem-
blies that to date have been recalcitrant to struc-
ture characterization.
EXPERIMENTAL PROCEDURES
Construct Design and Expression
Constructs of all chimeras were synthesized by GenScript
and then cloned into a modified pFastBac1 vector (Invitro-
gen) containing an HA signal sequence and a FLAG tag at
the N terminus, and a 103 His tag at the C terminus. ForA2AAR constructs, fusion proteins in the ICL3 were initially inserted between
residues L208 and R222. The C terminus was truncated to residue A317 to
minimize flexibility. For b2AR, fusion proteins in the ICL3 were inserted
between residues L230 and K263. The C terminus was truncated to residue
K348. The N terminus was left intact in both receptors. Recombinant baculo-
virus were generated with the Bac-to-Bac system (Invitrogen) and used to
infect Sf9 cells. Fifty microliters of P0 baculovirus was used to infect 5 ml of
Sf9 cells at a density of 2–3 3 106 cells/ml. Cells were grown at 27C for
48 hr prior to being harvested.
Purification
For small scale analysis of chimeric receptors, 5 ml of frozen Sf9 cells were
thawed in buffer containing 20 mM HEPES pH 7.5, 10 mM NaCl, 10 mM
MgCl2, 20 mM KCl, and Protease Inhibitor cocktail tablets (1 tablet per 50 ml
buffer; Roche). Dounce homogenization and centrifugation at 14,000 3 g
was carried out to disrupt intact cells and to remove unwanted soluble and
membrane associated proteins, and repeated twice with the addition of 1 M
NaCl in the buffer. Remaining membranes containing receptors were resus-
pended in buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 2 mg/ml
iodoacetamide, and an appropriate ligand (1 mM timolol for b2AR constructs
and 4 mM theophylline for A2AAR constructs). Membranes were allowed to
rock for 30 min at 4C, followed by solubilization with 0.5% (w/v) DDM and
0.1% (w/v) CHS for 2–4 hr at 4C. Solubilized membranes were spun down
at 14,000 3 g for 45 min, and the resulting supernatant was incubated with
50–100 ml TALON IMAC resin (Clontech) overnight in the presence of 20 mM
imidazole. TALON resin was spun down at 5003 g, resuspended in buffer con-
taining 50 mM HEPES pH 7.5, 150 mM NaCl, 0.05% (w/v) DDM, 0.01% (w/v)
CHS, 25 mM imidazole, and applied to a gravity column (Poly-Prep, Bio-Rad).
Protein was washed with an additional 20 column volumes (CV) of the same
resuspension buffer, and then eluted with buffer containing 50 mM HEPES
pH 7.5, 150 mMNaCl, 0.05% (w/v) DDM, 0.01% (w/v) CHS, and 250 mM imid-
azole. Fractions containing protein as determined by colorimetric Bradford
assay were pooled together. For A2AAR constructs, 800 mM NaCl was used
in place of 150 mM NaCl. All purification buffers were prechilled on ice and
purifications were carried out at 4C., 2012 ª2012 Elsevier Ltd All rights reserved 973
Figure 7. Structural Comparison of A2AAR
Solved by Different Engineering Methods
(A) High-resolution crystal structure of A2AAR-
BRIL PDB ID 4EIY (green), superimposed with
A2AAR-T4L (PDB ID 3EML, yellow) and thermo-
stabilized A2AAR (PDB ID 3PWH, blue).
(B) Expanded view of the junction site enclosed by
the red box in (A). The cytoplasmic ends of helix V
and helix VI of A2AAR-BRIL and thermostabilized
A2AAR superimpose very well, whereas the helices
of A2AAR-T4L must diverge to accommodate the
insertion of T4L (T4L domain not shown).
(C) Superimposition of the fused BRIL (PDB ID
4EIY, green), with standalone BRIL (PDB ID 1M6T,
orange), cytochromeb562withheme (PDB ID256B,
magenta), and NMR models of apocytochrome
b562 (PDB ID1YYX, gray) suggest high rigidity in the
protein core (bottom half) and high flexibility in the
termini and loop II (top half), especially in the apo
structures.
See also Figure S2.
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Fusion Partners for GPCR StabilizationFor purifications intended for crystallization trials, the above procedure was
used with the following modifications: (1) 1 l of frozen Sf9 cells was used, and
TALON resin bed volume was increased to 0.5 ml, typically providing1–2 mg
of purified receptor, (2) for b2AR constructs, 1 mM timolol was present in all
buffers during and after solubilization, up until reconstitution in LCP; 20 ml
PNGaseF (New England Biolabs) was added after the initial 20 CV wash and
allowed to incubate overnight before elution to deglycosylate the receptor,
and (3) for A2AAR constructs, 4 mM theophylline was present during solubiliza-
tion, and exchanged for 100 mMZM241385 on TALON resin and maintained in
all subsequent steps up until reconstitution in LCP.
For purifications intended for FRAP studies, the following modifications
were made: Packed TALON resin was resuspended in 5 ml wash buffer,
followed by the addition of 5–10 ml of 5 mg/ml Cy3-mono NHS ester (GE
Healthcare) dissolved in dimethylformamide. Protein was allowed to incubate
with the dye at 4C for 2–3 hr in darkness. Free dye was then removed by
flowing additional wash buffer through resin until the pink color could no longer
be visually observed in the flowthrough, followed by elution as usual. All steps
after dye labeling were carried out in darkness to prevent photobleaching.
SDS-PAGE and Immunoblotting
Protein samples were mixed with LDS sample buffer (Novex), separated on
10% Bis-Tris gels (Novex) at 130 V, and stained with Coomassie SimplyBlue
SafeStain (Novex). For western blots, proteins were transferred from gels to
nitrocellulose membranes using the iBlot Dry Blotting System and probed
with monoclonal anti-FLAG M2 alkaline phosphatase antibody (Sigma) for at
least 1 hr. Membranes were then washed in PBS, and antibodies were visual-
ized with SIGMAFAST BCIP/NBT (Sigma).
Analytical Size Exclusion Chromatography
Purified receptor constructs were applied to a Sepax Nanofilm SEC-250
column (4.6 3 250 mm) using an Agilent model 1200 HPLC system at a flow
rate of 0.5 mL/min and signal detection set to 350 nm. Prior to sample injection
the column was equilibrated in 50 mM HEPES pH 7.5, 500 mM NaCl, 2% (v/v)
glycerol, 0.05% (w/v) DDM (Affymetrix), and 0.01% (w/v) CHS (Sigma). Sample
reservoirs and column were maintained at 4C throughout analysis.
Thermostability Assay
N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM) dye (In-
vitrogen) was dissolved in DMSO (Sigma) at 4 mg/ml as a stock solution for
future use. The stock solutionwas kept at80Canddiluted 1:40 in dyedilution
solution (10 mM buffer, 500 mM NaCl, 10% [v/v] glycerol, 0.025% [w/v] DDM
and 0.005% [w/v] CHS) before use. The thermal denaturation assay was per-
formed with total volume of 200 ml sample in a quartz fluorometer cuvette
(Starna Cells, Atascadero, CA). Receptor (4 mg) was diluted in the appropriate
buffer solution to a final volumeof 200ml. Fivemicroliters of the diluted dye solu-974 Structure 20, 967–976, June 6, 2012 ª2012 Elsevier Ltd All rightstion was then added to the protein solution and incubated for 30 min at 4C in
darkness. The mixed solution was transferred to a cuvette and the data were
collected by a Cary Eclipse spectrofluorometer (Varian, USA) with a tempera-
ture ramping rate of 2C/min. The excitation wavelength was 387 nm and the
emission wavelength was 463 nm. All assays were performed over a tempera-
ture range starting from 20C to 90C. The stability data were processed with
GraphPad Prism (GraphPad Software, San Diego, CA).
Crystallization
In meso crystallization methods for membrane proteins have been described
in detail (Caffrey and Cherezov, 2009). Protein solution was mixed
with a molten lipid mixture of 10:1 (w/w) monoolein/cholesterol, at a ratio of
40% (w/w) protein with 60% (w/w) lipid in a custom syringe mixer. A syringe
containing reconstituted LCP was loaded onto an automated crystallization
robot (NT8-LCP, Formulatrix) and 35–50 nl of LCP dispensed onto 96-well
glass sandwich plates (Marienfeld), and then overlaid with 800 nl of precipitant
solution. Drops were manually sealed with a coverslip and incubated and
imaged at 20C in an automatic incubator/imager, RockImager 1000 (Formu-
latrix). Precipitants were all from homemade screens made and aliquoted into
96 well plates. Crystals of both b2AR-BRIL and A2AAR -BRIL grew within
7 days.
LCP-FRAP
Cy3-labeled protein for LCP-FRAP analysis was reconstituted into LCP and
dispensed onto glass sandwich plates as described in the crystallization
section. The setup for automated high-throughput LCP-FRAP analysis has
been described (Xu et al., 2011a). Briefly, LCP sandwich plates were loaded
onto a custom built LCP-FRAP station consisting of a Zeiss AxioImager A1
fluorescent microscope, a Micropoint dye cell laser (Photonic Instruments), a
cooled CCD FireWire camera CoolSnap HQ2 (Photometrics), and an auto-
mated XYZ microscope stage MS-2000 (Applied Scientific Instrumentation).
Each LCP drop was then bleached by firing 15–20 laser pulses at a 25 Hz pulse
rate. Fluorescence images were taken immediately before and after bleaching.
After a recovery period of 30 min, images were taken again to determine fluo-
rescence recovery, and analyzed by ImagePro Advanced Microscopy Suite
(Media Cybernetics).
X-Ray Data Collection
Crystallographic data were collected on the 23ID-B/D beamline (GM/CA CAT)
of the Advanced Photon Source at the Argonne National Laboratory using
a 10 mm collimated minibeam at a wavelength of 1.0330 A˚ and a MarMosaic
300 detector. To reduce radiation damage, crystals were translated to a fresh
position, if possible, or replaced after collecting 5–10 frames at 3 s exposure
and 1 oscillation with unattenuated beam. For details on the A2AAR-BRIL
structure determination, please refer to Liu et al. (2012).reserved
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